PMID- 37504365
OWN - NLM
STAT- MEDLINE
DCOM- 20230731
LR  - 20230731
IS  - 1718-7729 (Electronic)
IS  - 1198-0052 (Print)
IS  - 1198-0052 (Linking)
VI  - 30
IP  - 7
DP  - 2023 Jul 21
TI  - The Effectiveness and Safety of Stereotactic Body Radiation Therapy (SBRT) in the 
      Treatment of Oligoprogressive Breast Cancer: A Systematic Review.
PG  - 6976-6985
LID - 10.3390/curroncol30070505 [doi]
AB  - Stereotactic body radiotherapy (SBRT) has emerged as a technique to treat 
      oligoprogressive sites among patients with breast cancer who are otherwise doing 
      well on systemic therapy. This study systematically reviewed the efficacy and 
      safety of SBRT in the setting of oligoprogressive breast cancer. A literature 
      search was conducted in the MEDLINE database. Studies regarding SBRT and 
      oligoprogressive breast cancer were included. Key outcomes of interest were 
      toxicity, local control, progression, and overall survival. From 863 references, 
      five retrospective single-center cohort studies were identified. All studies 
      included patients with both oligometastatic and oligoprogressive disease; 112 
      patients with oligoprogressive breast cancer were identified across these 
      studies. Patient age ranged from 22 to 84, with a median of 55 years of age. Most 
      patients had hormone-receptor-positive and HER2-negative disease. SBRT doses 
      varied from 24 to 60 Gy in 1-10 fractions based on the location/size of the 
      lesion. Forty toxicity events were reported, of which the majority (n = 25, 
      62.5%) were grade 1-2 events. Among 15 patients who received SBRT concurrently 
      with a CDK4/6 inhibitor, 37.5% of patients experienced grade 3-5 toxicities. 
      Progression-free and overall survival ranged from 17 to 57% and 62 to 91%, 
      respectively. There are limited data on the role of SBRT in oligoprogressive 
      breast cancer, and prospective evaluation of this strategy is awaited to inform 
      its safety and efficacy.
FAU - Yan, Bernie
AU  - Yan B
AUID- ORCID: 0000-0002-0546-0327
AD  - Faculty of Health Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada.
FAU - Ramadan, Sherif
AU  - Ramadan S
AD  - Department of Radiation Oncology, London Health Sciences Centre, London, ON N6A 
      5W9, Canada.
FAU - Jerzak, Katarzyna J
AU  - Jerzak KJ
AD  - Department of Medicine, Sunnybrook Odette Cancer Centre, Toronto, ON M4N 3M5, 
      Canada.
FAU - Louie, Alexander V
AU  - Louie AV
AD  - Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON 
      M4N 3M5, Canada.
FAU - Donovan, Elysia
AU  - Donovan E
AD  - Department of Radiation Oncology, Juravinski Cancer Centre, Hamilton Health 
      Sciences, Hamilton, ON L8V 5C2, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20230721
PL  - Switzerland
TA  - Curr Oncol
JT  - Current oncology (Toronto, Ont.)
JID - 9502503
SB  - IM
MH  - Humans
MH  - Young Adult
MH  - Adult
MH  - Middle Aged
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - *Radiosurgery/methods
MH  - Retrospective Studies
MH  - *Breast Neoplasms/radiotherapy
PMC - PMC10378468
OTO - NOTNLM
OT  - SBRT
OT  - breast cancer
OT  - oligoprogression
COIS- Alexander Louie discloses that he received speaker's fees and advisory board 
      participation from AstraZeneca, unrelated to this project. Katarzyna Jerzak 
      discloses the following potential COIs. She has consultant/advisory board 
      member/honoraria for: Amgen, AstraZeneca, Apo Biologix, Eli Lilly, Esai, Genomic 
      Health, Gilead Sciences, Knight Therapeutics, Merck, Myriad Genetics Inc., 
      Pfizer, Roche, Seagen, Novartis, Viatris. She has received research grants from: 
      AstraZeneca, Eli Lilly, Seage. Elysia Donovan: Sherif Ramadan, and Bernie Yan 
      have no disclosures.
EDAT- 2023/07/28 13:10
MHDA- 2023/07/31 11:42
PMCR- 2023/07/21
CRDT- 2023/07/28 08:35
PHST- 2023/06/13 00:00 [received]
PHST- 2023/07/14 00:00 [revised]
PHST- 2023/07/19 00:00 [accepted]
PHST- 2023/07/31 11:42 [medline]
PHST- 2023/07/28 13:10 [pubmed]
PHST- 2023/07/28 08:35 [entrez]
PHST- 2023/07/21 00:00 [pmc-release]
AID - curroncol30070505 [pii]
AID - curroncol-30-00505 [pii]
AID - 10.3390/curroncol30070505 [doi]
PST - epublish
SO  - Curr Oncol. 2023 Jul 21;30(7):6976-6985. doi: 10.3390/curroncol30070505.